Keywords: Johnson & Johnson, Velcade, EU submission, Non-Hodgkin's lymphoma, Janssen-Cilag

Johnson & Johnson pulls EU submission for Velcade use in NHL

Article | 05 July 2012

Print This

The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson’s (NYSE: JNJ) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in